Journal of Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rozenfeld, V.
Right arrow Articles by Kleyman, E.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Pharmacy Practice, Vol. 14, No. 1, 54-69 (2001)
DOI: 10.1106/8WA6-F8NA-HTY5-H2GT

The Year in Review: Rheumatology

Vitalina Rozenfeld

Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 1 University Plaza, Brooklyn, NY 11201, Lenox Hill Hospital, Pharmacy Department, 100 E. 77th Street, New York, NY 10021

Larisa Chagan

Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 1 University Plaza, Brooklyn, NY 11201

Evgenia Kleyman

Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 1 University Plaza, Brooklyn, NY 11201

Pharmacologic management of rheumatoid arthritis has been a subject of extensive research within the last several years. Novel nonsteroidal anti-inflammatory drugs have entered the arena offering equal efficacy with an improved toxicity profile. The selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, are described. New disease modifying antirheumatic drugs include leflunomide, etanercept, and infliximab. Methotrexate, a widely used antirheumatic agent, has been continuously studied with other disease modifying therapies, such as sulfasalazine, hydroxychloroquine, and cyclosporin. Therapeutic principles of rheumatoid arthritis therapy, as well as the role of new treatment modalities is discussed in this review.

Key Words: rheumatoid arthritis • cyclooxygenase-2 inhibitors • leflunomide • etanercept • infliximab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?